Surrozen, Inc. (NASDAQ:SRZN – Free Report) – Research analysts at HC Wainwright issued their FY2024 earnings estimates for shares of Surrozen in a note issued to investors on Thursday ...

HC Wainwright analyst S. Buck forecasts that the company will post earnings per share of ($12.15) for the year. HC Wainwright has a “Buy” rating and a $16.00 price objective on the stock.

NEW YORK--(BUSINESS WIRE)--H.C. Wainwright & Co., LLC, announced its #1 Ranking by transaction volume for the calendar year of 2024, maintaining the Firm’s top position for 11 consecutive years ...

Fintel reports that on February 7, 2025, HC Wainwright & Co. initiated coverage of Vertical Aerospace (NYSE:EVTL) with a Buy recommendation. As of January 28, 2025, the average one-year price ...

Fintel reports that on February 3, 2025, HC Wainwright & Co. initiated coverage of CRISPR Therapeutics (LSE:0VRQ) with a Buy recommendation. There are 575 funds or institutions reporting positions ...

Tuesday, H.C. Wainwright reaffirmed its Buy rating on Northern Dynasty Minerals (NYSE:NAK) with a steady price target of $1.30, representing significant upside from the current trading price of $0.65.

In 2024 H.C. Wainwright also held the top position in PlacementTracker's Market League Tables for At-the-Market (ATM) Offerings representing 72 transactions. In addition to presently serving as ...

H.C. Wainwright initiated coverage of Harrow (HROW) with a Buy rating and $57 price target Harrow is a commercial-stage company focused on the development and commercialization of ophthalmic ...

H.C. Wainwright analyst Matthew Caufield initiated coverage of Surrozen (SRZN) with a Buy rating and $32 price target Surrozen is advancing novel therapies based on the selective modulation of the ...

Number 1 Investment Bank for Confidentially Marketed Public Offerings, Registered Direct, Private Placement, and At-the-Market (ATM) Offerings NEW YORK, January 27, 2025--(BUSINESS WIRE)--H.C.